AU Patent

AU2016219555B2 — Aqueous suspensions of TMC278

Assigned to Janssen Sciences Ireland ULC · Expires 2017-08-10 · 9y expired

What this patent protects

Abstract This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable 5 carrier, and the use of such pharmac…

USPTO Abstract

Abstract This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable 5 carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016219555B2
Jurisdiction
AU
Classification
—
Expires
2017-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.